Total Funding
47
34
Total FundingPost-IPO Equity raised
Growth Score
-8 pts
Heat Score
0 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
155340
Forty Seven is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways.
Acquired by 
Gilead Sciences
Irving L. Weissman: FounderPast Role: Stem Cell Therapeutics, Director- Jens-Peter Volkmer: Founder & VP Research & Early Development
About the Company
Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways based on technology licensed from Stanford University. Forty Seven's lead program, 5F9, is a monoclonal antibody against the CD47 receptor, a "don't eat me" signal that cancer cells commandeer to
avoid being ingested by macrophages. This antibody is currently being evaluated in six clinical studies in patients with solid tumors, acute myeloid leukemia, non-Hodgkin's lymphoma and colorectal carcinoma.
